Pfizer halts work on hemophilia gene therapy, Nikkei reports
Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...
Alight chairman William Foley to step down, Russell Fradin to succeed
Alight (ALIT) announced that its board of directors appointed Russell Fradin as its chairman of the board of directors, succeeding William ...
Why Pfizer's Stock Price Isn't Reflecting Its True Value
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
Pfizer: Danuglipron Could Tip The Scale In A Few Years, But For Now, Sell
Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...
The Industry Veteran CEO: Friend Or Foe?
Director nominees with CEO experience have long featured in Board slates put forward by activist investors. Those candidates were typically from outs ...